STRIkER
Phase NA Withdrawn
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
Phase 1/2 Withdrawn
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Withdrawn
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Phase 2 Withdrawn
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Phase 1/2 Withdrawn
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
Phase 1 Withdrawn
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Phase 1/2 Withdrawn
FOODPANC
Phase NA Withdrawn
BESTa
Phase NA Withdrawn
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Phase 2 Withdrawn
INAVO-CRC
Phase 2 Withdrawn
Living Donor Liver Transplantation for CRC Liver Metastases
Phase NA Withdrawn
Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)
Withdrawn
Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis
Phase NA Withdrawn
Does Genetic Susceptibility for Bleeding Affect Quantitative Faecal Immunochemical Test (qFIT) Results?
Withdrawn
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Phase 2 Withdrawn
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
Phase 1 Withdrawn
PRISM
Phase 2 Withdrawn
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Phase 2 Withdrawn
Imaging of the Esophagus Using a SECM Capsule
Phase NA Withdrawn
COMUNITY
Phase 2 Withdrawn
A Percutaneous Ultrasound Device With Needle Guide for Vascular Access
Phase NA Withdrawn
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
Phase 2 Withdrawn
Metabiomics Colon Cancer Clinical Research Study
Withdrawn
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
Phase 2 Withdrawn
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Phase 2 Withdrawn
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Phase 1 Withdrawn
LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)
Phase 1/2 Withdrawn
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Phase 1 Withdrawn
EMPIRE
Phase 2 Withdrawn
Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2)
Phase NA Withdrawn
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
Phase NA Withdrawn
Reduction of Conscious Sedation Requirements by Olfactory Stimulation
Phase NA Withdrawn
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Phase 1/2 Withdrawn
Dyadic Text-Messaging Micro-Intervention
Phase NA Withdrawn
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Phase 1 Withdrawn
A Trial of SHR1258 in Patients With Biliary Tract Cancer
Phase 2 Withdrawn
PRIMUS006
Phase 2 Withdrawn
DIGELECTROSTIM
Phase NA Withdrawn
TCR1020-CD8 T Cells in KRAS-mutated Cancers
Phase 1 Withdrawn
TRACT DNA
Withdrawn
FORTIFIDE
Phase 1/2 Withdrawn
A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer
Withdrawn
Defining Musical Toxicity and Its Effect on Patient Well-being
Withdrawn
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
Withdrawn
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Phase 2 Withdrawn
Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-
Phase 2 Withdrawn
Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
Phase 2 Withdrawn
Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy
Withdrawn
CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Phase 2 Withdrawn